Lykos Therapeutics

Lykos Therapeutics was created to handle the commercialization path for MDMA-assisted therapy for PTSD after the research program incubated inside MAPS. That makes it the company most directly associated with the first serious attempt to push a psychedelic-assisted therapy through the modern FDA approval process.

Regulatory position

In June 2024, the FDA's Psychopharmacologic Drugs Advisory Committee reviewed NDA 215455 for midomafetamine capsules. The agency briefing package shows how far the program advanced, but the FDA later issued a Complete Response Letter rather than approving the drug, leaving Lykos in a redesign-and-rebuild position rather than a launch position.

The practical takeaway is that Lykos is no longer just a company profile, it is also a case study in the regulatory standards psychedelic sponsors will be judged against.

Trial footprint

The core public trial record around Lykos includes the two multi-site Phase 3 PTSD studies MAPP1 (NCT03537014) and MAPP2 (NCT04077437), plus the open-label extension study MAPPUSX (NCT04714359). Those registry records matter because they pin the program to concrete study IDs, status pages, and protocol-era metadata rather than only company narrative.

What to watch

For now, the central questions are whether Lykos can define a credible new Phase 3 path, how FDA concerns about evidence and oversight get addressed, and whether the company can convert a pioneering psychedelic program into an approval-grade submission. Until that happens, Lykos remains important less as a commercial winner and more as the sector's clearest regulatory stress test.